Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. - Wikidata - awgldk - TriplyDB

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

http://www.wikidata.org/entity/Q35154039

about

Predictors of clinical response to immunotherapy with or without radiotherapy The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients New immunotherapies targeting the PD-1 pathway Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Targeting mutant NRAS signaling pathways in melanoma.Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e.Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.NRAS-mutant melanoma: current challenges and future prospect The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Binimetinib for the treatment of NRAS-mutant melanoma.Targeting Melanoma with Cancer-Killing Viruses.Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Genetic progression of malignant melanoma.Ipilimumab in melanoma.Gene-expression profiling to predict responsiveness to immunotherapy.KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.Interaction of molecular alterations with immune response in melanoma.Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.Melanoma driver mutations and immune therapy.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.Targeted treatment of advanced NRAS-mutated melanoma.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Emerging biomarkers for cancer immunotherapy in melanoma.Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells.Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.MEK inhibitors for the treatment of NRAS mutant melanoma Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond

P2860

Q26771870-E2A7B9EF-FF01-43D6-8170-E83FB60F645E Q26797478-451C318C-12CB-46A4-BCDE-E826174237CF Q27010018-322881AA-C6E6-4546-BF90-551C367A02FB Q27853331-D42D32C4-D2C5-4108-AEF7-37BDEEDFE9E8 Q33887664-FED7F5A5-E136-48EF-AFA6-F821C5745B9C Q36072022-E47C02BB-077D-41C2-80B3-1F459B4EB013 Q36173638-642A4BE9-5B4B-41E9-872E-B66BE4A756C2 Q36902066-8782B765-3C3E-4E2C-85FD-7AF7538DC294 Q37059782-203DAA37-EDE6-4648-A572-18FCAF425C9A Q37114367-B39FCDE3-E52F-47F9-87A0-BB80B9CC8E43 Q37319470-87169963-A404-43C6-B795-D4717E4982ED Q37641753-EA2BB00F-0985-49B5-9D71-95C14D03B029 Q37708989-7290767A-17D2-4B20-B5B4-020AD2E015CE Q38377528-DECF8E40-6B5D-4706-A8D3-A2635531636F Q38575000-E9D408A3-C810-48ED-B3E2-4738940BAA1B Q38598958-E98C750A-A4AD-410C-8CF0-747EEECFBE6C Q38620826-533CBDA6-F403-4744-BE06-9120CD22A8CE Q38636033-E16B4A7A-09BF-4C41-924F-4C5928AC4085 Q38676416-D6A1952D-F850-48F8-B468-93F3D223B001 Q38689912-74002C04-D57B-4BFA-A9E5-F6468716CD31 Q38771870-6EFAA9A3-9D08-43B9-BBF9-BE2B4256D456 Q38893697-2C35C49D-CFD2-4578-B988-6F81E6FB05AC Q39005203-7248F38E-3C68-494A-8480-24B0FFB246FC Q39078976-99559B6C-399F-47AF-81E1-9B547845FB7D Q39329609-8558BA3A-4F72-49C9-9994-552F6DFF29EA Q41592696-1E6BD5B0-BE2B-4755-91BB-BB7602FF8219 Q42034581-BB295B87-617E-41B1-BC2B-EF49CDBE295C Q42369277-47DE907B-808F-4E15-B79A-F2D2F4DCC299 Q43147493-426CA478-F54F-4D5D-87BF-314BAF15A29F Q46865924-87F08A68-5814-4BA2-A79A-F333F15B31C5 Q47118608-5B9A186E-39EF-4570-9B7E-5D67C8443111 Q47227422-17C4A77F-9F0D-428E-A256-572150F9CBA2 Q47292249-FE3B7EBF-0181-4BEC-9C36-974FBB96D630 Q50058145-A759716B-9A05-462F-86D6-B9E7B37789CD Q51187540-55DF1266-8790-46A6-835E-1565C1F3845D Q52604125-E55E3B2C-4C14-4EAE-B931-9B50B1176966 Q52801913-FC04D2C9-BA4C-4F67-9D71-396D4BD70240 Q55516983-96EBC0DB-5A37-49BB-AD37-332E046429F5 Q56889985-4B8856FA-F28A-4106-B9D0-F01A78F5368E Q56891609-B7D8763E-1405-47CE-A3C3-8EDA15D0CDA6

P2860

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

http://www.wikidata.org/entity/Q35154039

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Impact of NRAS mutations for p ...... treated with immune therapies.

@ast

Impact of NRAS mutations for p ...... treated with immune therapies.

@en

type

label

Impact of NRAS mutations for p ...... treated with immune therapies.

@ast

Impact of NRAS mutations for p ...... treated with immune therapies.

@en

prefLabel

Impact of NRAS mutations for p ...... treated with immune therapies.

@ast

Impact of NRAS mutations for p ...... treated with immune therapies.

@en

P1433

Q35154039-8DDB4620-E7C2-481F-B5F6-EC33A6274554

P1476

Q35154039-19AFF622-2B75-41E8-B121-0B604ACD9077

P2093

Q35154039-59C30F52-9C6A-4730-9969-8AD7045EAD3F

Q35154039-822C6B86-E439-4F20-957E-EC7B24595A62

Q35154039-8D083418-3B05-4A20-AD31-7FE9065779FE

Q35154039-92A0A0A7-0A86-4151-8DF7-EA5858AD89A5

Q35154039-9716EACD-35B2-40C7-9B79-0358B7C62B9C

Q35154039-B034D011-98F5-45CA-B4B3-C49D23B02076

Q35154039-B19DC430-931F-4F15-B742-8422080259B2

Q35154039-BBC48183-8AFC-4D82-8EE1-92C826298CC3

Q35154039-BF8C8578-CD7A-4422-85C7-372C4917CD9A

Q35154039-BF94A613-F345-414E-9A48-E8E5AE01881B

P2860

Q35154039-179C4FAE-8370-4B05-9CE5-E2AA16728A4D

Q35154039-3E0B33D9-93DB-4D59-807F-8431C15AEFC4

Q35154039-3F95194D-BAF6-4D71-80AD-9C0165EA3394

Q35154039-3FE3E2B3-EC35-4490-8836-C19E5388DB2E

Q35154039-4066742D-6849-48AD-A998-DA2206C4FD32

Q35154039-4175EE08-40D1-4D18-9A42-ED0A14A3939A

Q35154039-48CF625E-8B2D-45A8-9F14-C232F0E83C5F

Q35154039-60FD312E-6B01-473E-8C7C-C43C423F0FDD

Q35154039-68DF9252-2A71-4972-968F-4B88B995115D

Q35154039-778A3D9E-C062-4329-8AC8-72B59576DA43

P304

Q35154039-B8E9154A-BE26-4B83-87BE-78DBE7D0CD09

P31

Q35154039-E59C94BD-7C82-4433-B15B-CE1BEF9F16D1

P356

Q35154039-1E06FE67-5082-4893-88D6-CFBD3AB675B4

P433

Q35154039-E953C7A1-DA86-4E2F-A155-A93873408A2A

P478

Q35154039-37220646-E73E-4193-B5A8-019A802DD14D

P50

Q35154039-A043480B-C804-4F03-A113-347E10CDCCB5

Q35154039-BD3D3744-ACCC-4710-8608-45C93F4D49D7

P577

Q35154039-6E3FAAF2-BB3B-4BBE-9270-5638C6707D09

P698

Q35154039-5D9297EF-E725-4BB7-8ADD-471AC688CF68

P932

Q35154039-CC0C5FE6-A11F-4392-99B5-65528731BFA9

P356

2326-6066.CIR-14-0207

P1433

Cancer immunology research

P1476

Impact of NRAS mutations for p ...... treated with immune therapies.

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Charles R Terry

http://www.w3.org/2001/XMLSchema#string

Douglas B Johnson

http://www.w3.org/2001/XMLSchema#string

Elizabeth G Berry

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Katherine S Panageas

http://www.w3.org/2001/XMLSchema#string

Marisa Flavin

http://www.w3.org/2001/XMLSchema#string

Marta Colgan

http://www.w3.org/2001/XMLSchema#string

Richard D Carvajal

http://www.w3.org/2001/XMLSchema#string

Ryan J Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

P304

288-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0207

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Christine M. Lovly

Gregory Daniel Ayers

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25736262

http://www.w3.org/2001/XMLSchema#string

P932

4351797

http://www.w3.org/2001/XMLSchema#string